#1 Clinical Trials Search in Europe

Danicopan

Danicopan, also known as ALXN2040 or ACH-0144471, is an investigational drug being studied in clinical trials for the treatment of rare blood and kidney disorders. This article summarizes key information about ongoing and completed clinical trials evaluating danicopan’s safety, efficacy, and pharmacokinetics in conditions like paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy.

Table of Contents

What is Danicopan?

Danicopan is a new medication being studied for the treatment of certain blood disorders and kidney diseases. It is also known by several other names, including ALXN2040, ACH-0144471, ACH-4471, ACH4471, and 4471[1]. These different names are often used interchangeably in medical literature and clinical trials, but they all refer to the same drug.

What Conditions Does Danicopan Treat?

Danicopan is primarily being investigated for the treatment of two main conditions:

  1. Paroxysmal Nocturnal Hemoglobinuria (PNH): This is a rare blood disorder where red blood cells break down earlier than they should. This can lead to various symptoms, including fatigue, shortness of breath, and an increased risk of blood clots[2].
  2. C3 Glomerulopathy (C3G) and related kidney diseases: These are rare kidney disorders that can lead to kidney failure. They include conditions such as C3 Glomerulonephritis, Dense Deposit Disease, and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)[3].

How Does Danicopan Work?

Danicopan works by targeting a specific part of the body’s immune system called the complement system. In particular, it inhibits a protein called factor D, which is part of what’s known as the alternative pathway of complement activation[4].

In conditions like PNH and C3G, the complement system becomes overactive and starts attacking the body’s own cells. By blocking factor D, Danicopan helps to reduce this harmful activity, potentially improving symptoms and slowing disease progression.

Clinical Trials and Research

Danicopan is currently being studied in several clinical trials:

  • For PNH, it’s being tested as an add-on treatment to existing therapies like Soliris® (eculizumab) or Ultomiris® (ravulizumab). These trials aim to see if Danicopan can help patients who still have symptoms despite current treatments[5].
  • For C3G and related kidney diseases, researchers are investigating whether Danicopan can improve kidney function and reduce protein in the urine, which is a sign of kidney damage[3].
  • Some trials are also looking at how Danicopan affects levels of certain proteins in the blood, which can give clues about how well the treatment is working[4].

How is Danicopan Administered?

Danicopan is taken orally, usually in the form of tablets or capsules. In most clinical trials, it’s given multiple times a day. The exact dose can vary depending on the condition being treated and other factors[6].

Some studies are looking at different formulations of Danicopan, including tablets, softgel capsules, and liquid-filled capsules, to see which might work best for patients[6].

Potential Side Effects

As with any medication, Danicopan may cause side effects. The full range of potential side effects is still being studied in clinical trials. Researchers are carefully monitoring patients for any adverse events, which are undesirable experiences associated with the use of a medical product[7].

It’s important to note that not everyone experiences side effects, and the benefits of the medication may outweigh the risks for many patients. Always discuss potential risks and benefits with your healthcare provider.

Future Prospects

Danicopan is still in the research and development phase. If current clinical trials show positive results, it could become an important new treatment option for patients with PNH, C3G, and related disorders[5].

Some studies are also looking at how Danicopan might be used in combination with existing treatments to provide better outcomes for patients[2].

As research continues, we may learn more about how Danicopan can be used most effectively and safely to help patients with these challenging conditions.

Aspect Details
Drug Name Danicopan (also known as ALXN2040, ACH-0144471)
Primary Conditions Studied Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis
Administration Oral tablet or capsule, typically 100-200 mg three times daily
Key Outcome Measures Changes in hemoglobin, LDH levels, reticulocyte count, proteinuria, kidney function
Trial Phases Phase 1, Phase 2, Phase 3
Special Populations Pediatric patients, patients with hepatic impairment
Combination Therapy Studied as add-on to complement inhibitors (e.g., eculizumab, ravulizumab) in some PNH trials

FAQ

  • What is danicopan and how does it work? Danicopan is an investigational oral medication that inhibits a part of the immune system called the complement alternative pathway. It is being studied as a potential treatment for rare blood and kidney disorders caused by overactivation of this pathway.
  • What conditions is danicopan being studied to treat? Danicopan is primarily being investigated for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It's also being studied for C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, which are rare kidney diseases.
  • How is danicopan administered in clinical trials? In most trials, danicopan is given as an oral tablet or capsule. The dosing regimens vary, but common doses range from 100 to 200 milligrams taken three times daily.
  • What are the main outcomes being measured in danicopan trials? Key outcomes include changes in hemoglobin levels, lactate dehydrogenase levels, reticulocyte count, and quality of life measures for PNH trials. For kidney disease trials, changes in proteinuria and kidney function are important outcomes.
  • Are there any known side effects of danicopan from clinical trials? While specific side effect data is not provided in the trial summaries, the studies are monitoring for treatment-emergent adverse events, serious adverse events, and laboratory abnormalities to assess the safety profile of danicopan.

Ongoing Clinical Trials on Danicopan

  • Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Danicopan for Adults with Chronic Spontaneous Urticaria Resistant to H1-Antihistamines

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

    Not recruiting

    1
    Investigated drugs:
    Czechia France Germany Hungary Italy Latvia +2

  • Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Greece Italy Poland Spain

Glossary

  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder where red blood cells break down earlier than normal, leading to symptoms like fatigue and difficulty breathing.
  • C3 Glomerulopathy: A rare kidney disease characterized by deposits of complement C3 protein in the kidneys, which can lead to kidney damage and failure.
  • Extravascular Hemolysis: The breakdown of red blood cells outside of blood vessels, often in the liver or spleen.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body.
  • Lactate Dehydrogenase (LDH): An enzyme released when cells are damaged or destroyed, often used as a marker of hemolysis in PNH.
  • Reticulocyte Count: A measure of immature red blood cells, which can indicate how well the body is producing new red blood cells.
  • Proteinuria: The presence of excess protein in the urine, which can be a sign of kidney damage.
  • Estimated Glomerular Filtration Rate (eGFR): A measure of how well the kidneys are filtering waste from the blood.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Complement Inhibitor (C5i): A type of medication that blocks part of the complement system, often used to treat PNH.

References

  1. https://clinicaltrials.gov/study/NCT03555539
  2. https://clinicaltrials.eu/trial/study-of-danicopan-with-ravulizumab-or-eculizumab-for-children-with-paroxysmal-nocturnal-hemoglobinuria-and-extravascular-hemolysis/
  3. https://clinicaltrials.gov/study/NCT03459443
  4. https://clinicaltrials.gov/study/NCT03124368
  5. https://clinicaltrials.gov/study/NCT05982938
  6. https://clinicaltrials.gov/study/NCT04940559
  7. https://clinicaltrials.gov/study/NCT03053102